Abstract
Letters15 July 1995Clarithromycin Therapy for Mycobacterium avium Complex BacteremiaRichard A. Chaisson and Constance A. BensonRichard A. ChaissonSearch for more papers by this author and Constance A. BensonSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-123-2-199507150-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Drs. Singh and Yu wonder whether the increased prevalence of gastrointestinal symptoms and worse survival in patients randomly assigned to receive clarithromycin, 2000 mg twice daily, could reflect undiagnosed adrenal insufficiency. We do not believe that the gastrointestinal toxicity observed in the high-dose clarithromycin arm was a result of adrenal insufficiency. Patients were randomly assigned to one of three treatment arms, and we did not observe significant imbalances in patient characteristics by treatment. Gastrointestinal toxicity is a well-known, dose-related complication of macrolide therapy. Earlier studies of high-dose clarithromycin in patients with HIV infection confirmed the higher incidence of ...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
